Synergistic activity of antibodies in the multicomponent 4CMenB vaccine

References

• Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. PubMed PMID: 30526162.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11. PubMed PMID: 27449148.
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–357. PubMed PMID: 6135869.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. a randomized controlled trial in Chile. JAMA. 1999;281(16):1520–1527. PubMed PMID: 10227322.
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14(2):67–79; discussion 79-80. PubMed PMID: 1812438.
   PubMedGoogle Scholar
• Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207; discussion 208-10. PubMed PMID: 1812432.
   PubMedGoogle Scholar
• Oster P, Lennon D, O’Hallahan J, et al.MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17–18):2191–2196. PubMed PMID: 15755593
   PubMed Web of Science ®Google Scholar
• Sevestre J, Hong E, Delbos V, et al. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: lessons of the Normandy campaign. Vaccine. 2017;35(32):4029–4033. PubMed PMID: 28624305.
   PubMed Web of Science ®Google Scholar
• Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62(10):4419–4424. PubMed PMID: 7927704; PubMed Central PMCID: PMCPMC303125.
   PubMed Web of Science ®Google Scholar
• Tani C, Stella M, Donnarumma D, et al. Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero(R) vaccine. Vaccine. 2014;32(11):1273–1279. PubMed PMID: 24462403.
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486–491. PubMed PMID: 16603616; PubMed Central PMCID: PMCPMC1459632.
   PubMedGoogle Scholar
• Burman C, Alderfer J, Snow VT. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp. J Clin Pharm Ther. 2020;45(2):270–281. PubMed PMID: 31820483.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, et al.Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–1820. PubMed PMID: 10710308
   PubMed Web of Science ®Google Scholar
• Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero((R)): prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34(7):875–880. PubMed PMID: 26686570.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al.A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103(29):10834–10839. PubMed PMID: 16825336; PubMed Central PMCID: PMCPMC2047628
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326. PubMed PMID: 4977280; PubMed Central PMCID: PMCPMC2138650.
   PubMed Web of Science ®Google Scholar
• Bash MC, Lynn F, Mocca B, et al. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers. Clin Vaccine Immunol. 2014;21(5):755–761. PubMed PMID: 24671551; PubMed Central PMCID: PMCPMC4018891.
   PubMedGoogle Scholar
• Giuliani MM, Biolchi A, Serruto D, et al.Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28(31):5023–5030. PubMed PMID: 20493284
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al.Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–19495. PubMed PMID: 20962280; PubMed Central PMCID: PMCPMC2984153
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636. PubMed PMID: 25882169.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, et al.Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–4974. PubMed PMID: 23954380
   PubMed Web of Science ®Google Scholar
• Stella M, Giuliani M, Biolchi A, et al. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. Hum Vaccin Immunother. 2020;16(4):945–948. PubMed PMID: 31770063; PubMed Central PMCID: PMCPMC7227617.
   PubMed Web of Science ®Google Scholar
• Abad R, Biolchi A, Moschioni M, et al. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB. Clin Vaccine Immunol. 2015;22(4):357–360. PubMed PMID: 25630407; PubMed Central PMCID: PMCPMC4375344.
   PubMed Web of Science ®Google Scholar
• Brehony C, Rodrigues CMC, Borrow R, et al.Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine. 2016;34(39):4690–4697. PubMed PMID: 27521232; PubMed Central PMCID: PMCPMC5012890
   PubMed Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, et al.Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. PubMed PMID: 30661831
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al.Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–1137. PubMed PMID: 20954968
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71–9. PubMed PMID: 20844462.
   PubMed Web of Science ®Google Scholar
• Esposito S, Prymula R, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005–2014. PubMed PMID: 25424810; PubMed Central PMCID: PMCPMC4186018.
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. PubMed PMID: 25424809; PubMed Central PMCID: PMCPMC4186040.
   PubMed Web of Science ®Google Scholar
• Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine. 2011;29(10):1968–1973. PubMed PMID: 21241734; PubMed Central PMCID: PMCPMC3043162.
   PubMed Web of Science ®Google Scholar
• Partridge E, Lujan E, Giuntini S, et al.The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine. 2017;35(33):4236–4244. PubMed PMID: 28651840; PubMed Central PMCID: PMCPMC5560085
   PubMed Web of Science ®Google Scholar
• Welsch JA, Senders S, Essink B, et al. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018;36(35):5309–5317. PubMed PMID: 30061029.
   PubMed Web of Science ®Google Scholar
• Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–7550. PubMed PMID: 33036804.
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340(8827):1074–1078. PubMed PMID: 1357461.
   PubMed Web of Science ®Google Scholar
• Ochoa-Azze RF. Cross-protection induced by VA-MENGOC-BC(R) vaccine. Hum Vaccin Immunother. 2018;14(5):1064–1068. PubMed PMID: 29420119; PubMed Central PMCID: PMCPMC5989903.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM, et al. The concept of “tailor-made,” protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine. 2005;23(17–18):2202–2205. PubMed PMID: 15755595.
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27 Suppl 2:B3–12. PubMed PMID: 19481313.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–1253. PubMed PMID: 23857274; PubMed Central PMCID: PMCPMC3901813
   PubMed Web of Science ®Google Scholar
• Arnold R, Galloway Y, McNicholas A, et al.Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–7106. PubMed PMID: 21803101
   PubMed Web of Science ®Google Scholar
• Wedege E, Bolstad K, Aase A, et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol. 2007;14(7):830–838. PubMed PMID: 17494638; PubMed Central PMCID: PMCPMC1951067.
   PubMedGoogle Scholar
• Rosenqvist E, Hoiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995;63(12):4642–4652. PubMed PMID: 7591118; PubMed Central PMCID: PMCPMC173667.
   PubMed Web of Science ®Google Scholar
• Wedege E, Hoiby EA, Rosenqvist E, et al. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun. 1998;66(7):3223–3231. PubMed PMID: 9632589; PubMed Central PMCID: PMCPMC108336.
   PubMed Web of Science ®Google Scholar
• Williams JN, Weynants V, Poolman JT, et al.Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens. Vaccine. 2014;32(11):1280–1286. PubMed PMID: 24486354
   PubMed Web of Science ®Google Scholar
• Mendum TA, Newcombe J, McNeilly CL, et al. Towards the immunoproteome of Neisseria meningitidis. PLoS One. 2009;4(6):e5940. PubMed PMID: 19529772; PubMed Central PMCID: PMCPMC2691954.
   PubMed Web of Science ®Google Scholar
• Williams JN, Skipp PJ, O’Connor CD, et al. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun. 2009;77(11):5080–5089. PubMed PMID: 19737898; PubMed Central PMCID: PMCPMC2772525.
   PubMed Web of Science ®Google Scholar
• Awanye AM, Chang CM, Wheeler JX, et al.Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis. Sci Rep. 2019;9(1):6843. PubMed PMID: 31048732; PubMed Central PMCID: PMCPMC6497663
   PubMedGoogle Scholar
• Wright JC, Williams JN, Christodoulides M, et al. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun. 2002;70(8):4028–4034. PubMed PMID: 12117908; PubMed Central PMCID: PMCPMC128133.
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen DA, Borriello SP. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine. 1996;14(1):49–53. PubMed PMID: 8821649.
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Borrow R, Fox AJ, et al. Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Vaccine. 1995;13(13):1207–1212. PubMed PMID: 8578805.
   PubMed Web of Science ®Google Scholar
• Danve B, Lissolo L, Mignon M, et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine. 1993;11(12):1214–1220. PubMed PMID: 8256502.
   PubMed Web of Science ®Google Scholar
• West D, Reddin K, Matheson M, et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun. 2001;69(3):1561–1567. PubMed PMID: 11179327; PubMed Central PMCID: PMCPMC98056.
   PubMed Web of Science ®Google Scholar
• Rokbi B, Mignon M, Maitre-Wilmotte G, et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun. 1997;65(1):55–63. PubMed PMID: 8975892; PubMed Central PMCID: PMCPMC174556.
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen DA, Stevenson P, Griffiths E, et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect Immun. 1994;62(7):2984–2990. PubMed PMID: 8005685; PubMed Central PMCID: PMCPMC302908.
   PubMed Web of Science ®Google Scholar
• Pettersson A, Kortekaas J, Weynants VE, et al. Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB. Vaccine. 2006;24(17):3545–3557. PubMed PMID: 16517031.
   PubMed Web of Science ®Google Scholar
• Pettersson A, Prinz T, Umar A, et al. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol Microbiol. 1998;27(3):599–610. PubMed PMID: 9489671.
   PubMed Web of Science ®Google Scholar
• Black JR, Dyer DW, Thompson MK, et al. Human immune response to iron-repressible outer membrane proteins of Neisseria meningitidis. Infect Immun. 1986;54(3):710–713. PubMed PMID: 3096888; PubMed Central PMCID: PMCPMC260227.
   PubMed Web of Science ®Google Scholar
• Sanders H, Norheim G, Chan H, et al. FetA antibodies induced by an outer membrane vesicle vaccine derived from a serogroup B meningococcal isolate with constitutive FetA expression. PLoS One. 2015;10(10):e0140345. PubMed PMID: 26466091; PubMed Central PMCID: PMCPMC4605655.
   PubMed Web of Science ®Google Scholar
• Marsay L, Dold C, Green CA, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: a phase I clinical trial. J Infect. 2015;71(3):326–337. PubMed PMID: 25982025; PubMed Central PMCID: PMCPMC4535279.
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Hoiby EA, Wedege E, et al. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis. 1993;167(5):1065–1073. PubMed PMID: 8486938.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Appleby L, Wright JC, et al. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun. 2001;69(6):3809–3816. PubMed PMID: 11349046; PubMed Central PMCID: PMCPMC98398.
   PubMed Web of Science ®Google Scholar
• Musacchio A, Carmenate T, Delgado M, et al. Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Vaccine. 1997;15(6–7):751–758. PubMed PMID: 9178478.
   PubMed Web of Science ®Google Scholar
• Carmenate T, Mesa C, Menendez T, et al. Recombinant Opc protein from Neisseria meningitidis reconstituted into liposomes elicits opsonic antibodies following immunization. Biotechnol Appl Biochem. 2001;34(1):63–69. PubMed PMID: 11483156.
   PubMed Web of Science ®Google Scholar
• Perez RE, Lasa AM, Rodriguez RS, et al. Scale-up of recombinant Opc protein production in Escherichia coli for a meningococcal vaccine. J Biotechnol. 2006;127(1):109–114. PubMed PMID: 16893582.
   PubMed Web of Science ®Google Scholar
• Hung MC, Heckels JE, Christodoulides M. The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. mBio. 2013;4(2): PubMed PMID: 23443003; PubMed Central PMCID: PMCPMC3585444. DOI:https://doi.org/10.1128/mBio.00041-13.
   Google Scholar
• Hung MC, Heckels JE, Christodoulides M. Potential of the adhesin complex protein of Neisseria meningitidis for next-generation meningococcal vaccines. Expert Rev Vaccines. 2013;12(9):981–984. PubMed PMID: 24053391.
   PubMed Web of Science ®Google Scholar
• Kolappan S, Coureuil M, Yu X, et al. Structure of the Neisseria meningitidis Type IV pilus. Nat Commun. 2016;7:13015. PubMed PMID: 27698424; PubMed Central PMCID: PMCPMC5059446.
   PubMed Web of Science ®Google Scholar
• Haghi F, Peerayeh SN, Siadat SD, et al. Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis. Vaccine. 2012;30(9):1710–1714. PubMed PMID: 22234267.
   PubMed Web of Science ®Google Scholar
• Maharjan S, Saleem M, Feavers IM, et al. Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis. Microbiology. 2016;162(2):364–375. PubMed PMID: 26678687.
   PubMedGoogle Scholar
• Rosenqvist E, Musacchio A, Aase A, et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun. 1999;67(3):1267–1276. PubMed PMID: 10024570; PubMed Central PMCID: PMCPMC96456.
   PubMed Web of Science ®Google Scholar
• Weynants VE, Feron CM, Goraj KK, et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun. 2007;75(11):5434–5442.
   PubMed Web of Science ®Google Scholar
• Wedege E, Lie K, Bolstad K, et al. Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice. Scand J Immunol. 2013;77(6):452–459. PubMed PMID: 23521186.
   PubMed Web of Science ®Google Scholar
• Cadieux N, Plante M, Rioux CR, et al. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun. 1999;67(9):4955–4959. PubMed PMID: 10456958; PubMed Central PMCID: PMCPMC96836.
   PubMed Web of Science ®Google Scholar
• Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun. 1999;67(11):5664–5675. PubMed PMID: 10531214; PubMed Central PMCID: PMCPMC96940.
   PubMed Web of Science ®Google Scholar
• Ying S, He J, Yu M, et al. Recombinant Neisseria surface protein A is a potential vaccine candidate against Neisseria meningitides serogroup B. Mol Med Rep. 2014;10(3):1619–1625. PubMed PMID: 24926810.
   PubMed Web of Science ®Google Scholar
• Martin D, Brodeur BR, Hamel J, et al. Candidate Neisseria meningitidis NspA vaccine. J Biotechnol. 2000;83(1–2):27–31. PubMed PMID: 11000456.
   PubMed Web of Science ®Google Scholar
• Martin D, Cadieux N, Hamel J, et al. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med. 1997;185(7):1173–1183. PubMed PMID: 9104804; PubMed Central PMCID: PMCPMC2196255.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Langley JM, Smith B, et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine. 2007;25(3):450–457. PubMed PMID: 17052819.
   PubMed Web of Science ®Google Scholar
• Hung MC, Salim O, Williams JN, et al. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infect Immun. 2011;79(9):3784–3791. PubMed PMID: 21708989; PubMed Central PMCID: PMCPMC3165472.
   PubMed Web of Science ®Google Scholar
• Bielecka MK, Devos N, Gilbert M, et al. Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins. Infect Immun. 2015;83(2):730–742. PubMed PMID: 25452551; PubMed Central PMCID: PMCPMC4294229.
   PubMed Web of Science ®Google Scholar
• Costoya L, Marzoa J, Ferreiros C, et al. Liposomes or traditional adjuvants: induction of bactericidal activity by the macrophage infectivity potentiator protein (Mip) of Neisseria meningitidis. APMIS. 2017;125(8):725–731. PubMed PMID: 28543600.
   PubMed Web of Science ®Google Scholar
• Sardinas G, Yero D, Climent Y, et al. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J Med Microbiol. 2009;58(Pt 2):196–208. PubMed PMID: 19141737.
   PubMed Web of Science ®Google Scholar
• Keiser PB, Gibbs BT, Coster TS, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine. 2010;28(43):6970–6976. PubMed PMID: 20732470.
   PubMed Web of Science ®Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29(7):1413–1420. PubMed PMID: 21199704.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H, Paynter J, Morgan J, et al.Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–1610. PubMed PMID: 28705462
   PubMed Web of Science ®Google Scholar
• Semchenko EA, Tan A, Borrow R, et al. The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2019;69(7):1101–1111. PubMed PMID: 30551148; PubMed Central PMCID: PMCPMC6743822.
   PubMed Web of Science ®Google Scholar
• Beernink PT, Welsch JA, Bar-Lev M, et al. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun. 2008;76(9):4232–4240. PubMed PMID: 18591239; PubMed Central PMCID: PMCPMC2519416.
   PubMed Web of Science ®Google Scholar
• Faleri A, Santini L, Brier S, et al. Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties. FASEB J. 2014;28(4):1644–1653. PubMed PMID: 24371123.
   PubMed Web of Science ®Google Scholar
• Malito E, Lo Surdo P, Veggi D, et al. Neisseria meningitidis factor H-binding protein bound to monoclonal antibody JAR5: implications for antibody synergy. Biochem J. 2016;473(24):4699–4713. PubMed PMID: 27784765; PubMed Central PMCID: PMCPMC6398935.
   PubMedGoogle Scholar
• Biagini M, Spinsanti M, De Angelis G, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA. 2016;113(10):2714–2719. PubMed PMID: 26888286; PubMed Central PMCID: PMCPMC4791009.
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–1263. PubMed PMID: 24626930; PubMed Central PMCID: PMCPMC4250092.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Bartolini E, Galli B, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018;8(1):3700. PubMed PMID: 29487324; PubMed Central PMCID: PMCPMC5829249.
   PubMed Web of Science ®Google Scholar
• Peschiera I, Giuliani M, Giusti F, et al. Structural basis for cooperativity of human monoclonal antibodies to meningococcal factor H-binding protein. Commun Biol. 2019;2:241. PubMed PMID: 31263785; PubMed Central PMCID: PMCPMC6595007.
   PubMed Web of Science ®Google Scholar
• Natali EN, Principato S, Ferlicca F, et al. Synergic complement-mediated bactericidal activity of monoclonal antibodies with distinct specificity. FASEB J. 2020;34:10329–10341. PubMed PMID: 32725956.
   PubMed Web of Science ®Google Scholar
• Figueroa J, Andreoni J, Densen P. Complement deficiency states and meningococcal disease. Immunol Res. 1993;12(3):295–311. PubMed PMID: 8288947.
   PubMed Web of Science ®Google Scholar
• Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol. 2009;46(14):2808–2817. PubMed PMID: 19477524.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ram S. Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, and evasion mechanisms. FEBS Lett. 2020;594:2670–2694. PubMed PMID: 32058583.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6(7):e1001027. PubMed PMID: 20686663; PubMed Central PMCID: PMCPMC2912398.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Vu DM, Vasudhev S, et al. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio. 2013;4(5):e00339–13. PubMed PMID: 24129254; PubMed Central PMCID: PMCPMC3812710.
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501–510. PubMed PMID: 16785547; PubMed Central PMCID: PMCPMC2248442.
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107(8):3770–3775. PubMed PMID: 20133713; PubMed Central PMCID: PMCPMC2840514.
   PubMed Web of Science ®Google Scholar
• Jarva H, Ram S, Vogel U, et al. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol. 2005;174(10):6299–6307. PubMed PMID: 15879129.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Pajon R, Ram S, et al. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun. 2015;83(4):1536–1545. PubMed PMID: 25644002; PubMed Central PMCID: PMCPMC4363443.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. Expert Rev Vaccines. 2022; 1–16. PubMed PMID: 34927511. DOI: https://doi.org/10.1080/14760584.2022.2017287
   Google Scholar